Aromatase inhibitors in premenopause: Great expectations fulfilled?

Research output: Contribution to journalArticlepeer-review

Abstract

Tamoxifen and GnRH analogues (GnRHa) represent the mainstay of endocrine manipulations in premenopausal women. The estrogen blockade obtained by aromatase inhibitors (AIs) plus GnRHa suppresses circulating estrogens more deeply than tamoxifen plus GnRHa. Retrospective and prospective evidence confirm a substantial activity for AIs and GnRHa in locally advanced and metastatic breast cancer. In early breast cancer inconsistent evidence emerged from 2 large randomized studies with anastrozole performing as tamoxifen in terms of DFS, but significantly worse as of OS while exemestane outperformed tamoxifen as of DFS particularly in very young and high-risk women. These findings support the use of AIs plus GnRHa in advanced breast cancer while long term efficacy and safety data are expected to define the appropriate indication of AIs in early breast cancer. In addition the clinical significance of persistent circulating estrogens and long term effects of estrogen deprivation in young women need further clarification.

Original languageEnglish
Pages (from-to)82-89
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume107
DOIs
Publication statusPublished - Nov 2016

Keywords

  • Review
  • Journal Article

Fingerprint Dive into the research topics of 'Aromatase inhibitors in premenopause: Great expectations fulfilled?'. Together they form a unique fingerprint.

Cite this